<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8"/>
    <meta property="og:url" content="https://www.thecerbatgem.com/2019/11/18/vbi-vaccines-nasdaqvbiv-receives-new-coverage-from-analysts-at-raymond-james.html"/>
    <meta property="og:site_name" content="The Cerbat Gem"/>
    <meta property="article:published_time" content="2019-11-18T15:20:18+00:00"/>
    <meta property="og:title" content="VBI Vaccines (NASDAQ:VBIV) Receives New Coverage from Analysts at Raymond James"/>
    <meta property="og:description" content="Raymond James began coverage on shares of VBI Vaccines (NASDAQ:VBIV) in a research report sent to investors on Thursday, The Fly reports. The firm issued an outperform rating and a $3.00 price target on the biopharmaceutical company’s stock. Several other brokerages have also recently issued reports on VBIV. Zacks Investment Research cut VBI Vaccines from […]"/>
  </head>
  <body>
    <article>
      <h1>VBI Vaccines (NASDAQ:VBIV) Receives New Coverage from Analysts at Raymond James</h1>
      <address><time datetime="2019-11-18T15:20:18+00:00">18 Nov 2019, 15:20</time> by <a rel="author" href="https://www.thecerbatgem.com/author/jessica" target="_blank">Jessica Moore</a></address>
      <figure>
        <img src="https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?w=250&amp;zc=1&amp;src=https://www.marketbeat.com/logos/vbi-vaccines-inc-logo.png"/>
      </figure>
      <p>Raymond James began coverage on shares of VBI Vaccines (NASDAQ:VBIV) in a research report sent to investors on Thursday, <a href="https://www.thefly.com/">The Fly</a> reports. The firm issued an outperform rating and a $3.00 price target on the biopharmaceutical company’s stock.</p>
      <p>Several other brokerages have also recently issued reports on VBIV. <a href="https://www.americanconsumernews.net/scripts/click.aspx?Zacks=1">Zacks Investment Research</a> cut VBI Vaccines from a buy rating to a hold rating in a research note on Wednesday, August 21st. <a href="https://www.americanconsumernews.net/scripts/click.aspx?ValuEngine=1&amp;Symbol=VBIV">ValuEngine</a> upgraded VBI Vaccines from a hold rating to a buy rating in a research note on Thursday, August 1st. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. The company has an average rating of Buy and an average target price of $3.81.</p>
      <p><a href="https://www.marketbeat.com/stocks/NASDAQ/VBIV/price-target/">VBI Vaccines stock</a> traded down $0.01 during midday trading on Thursday, reaching $0.59. 43,410 shares of the stock traded hands, compared to its average volume of 2,156,749. The company has a 50-day simple moving average of $0.55 and a two-hundred day simple moving average of $1.00. The company has a current ratio of 1.88, a quick ratio of 1.84 and a debt-to-equity ratio of 0.01. The firm has a market cap of $100.25 million, a PE ratio of -0.60 and a beta of 0.52. VBI Vaccines has a 12-month low of $0.47 and a 12-month high of $2.20.</p>
      <p>VBI Vaccines (NASDAQ:VBIV) last announced its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.02). The company had revenue of $0.65 million during the quarter, compared to analysts’ expectations of $0.90 million. VBI Vaccines had a negative net margin of 1,458.97% and a negative return on equity of 70.54%. Equities research analysts anticipate that VBI Vaccines will post -0.47 earnings per share for the current year.</p>
      <p>In other VBI Vaccines news, CEO Jeff Baxter bought 150,000 shares of the business’s stock in a transaction dated Monday, September 30th. The shares were acquired at an average price of $0.50 per share, with a total value of $75,000.00. Following the transaction, the chief executive officer now owns 608,255 shares of the company’s stock, valued at $304,127.50. The acquisition was disclosed in a filing with the SEC, which is accessible through <a href="https://www.sec.gov/Archives/edgar/data/764195/000149315219014759/xslF345X03/ownership.xml">this link</a>. Also, major shareholder Perceptive Advisors Llc bought 20,000,000 shares of the business’s stock in a transaction dated Monday, September 23rd. The shares were acquired at an average cost of $0.50 per share, for a total transaction of $10,000,000.00. The disclosure for this purchase can be found <a href="https://www.sec.gov/Archives/edgar/data/764195/000089924319024191/xslF345X03/doc4.xml">here</a>. Insiders bought a total of 30,212,000 shares of company stock valued at $15,105,440 in the last quarter. Company insiders own 10.50% of the company’s stock.</p>
      <p>Several hedge funds and other institutional investors have recently modified their holdings of VBIV. General American Investors Co. Inc. raised its position in shares of VBI Vaccines by 23.2% during the 2nd quarter. General American Investors Co. Inc. now owns 2,174,264 shares of the biopharmaceutical company’s stock worth $2,544,000 after acquiring an additional 409,800 shares in the last quarter. JPMorgan Chase &amp; Co. acquired a new stake in shares of VBI Vaccines during the 2nd quarter worth about $25,000. Bank of Montreal Can raised its position in shares of VBI Vaccines by 71.8% during the 2nd quarter. Bank of Montreal Can now owns 37,604 shares of the biopharmaceutical company’s stock worth $44,000 after acquiring an additional 15,717 shares in the last quarter. Charles Schwab Investment Management Inc. raised its position in shares of VBI Vaccines by 664.5% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 200,848 shares of the biopharmaceutical company’s stock worth $235,000 after acquiring an additional 174,576 shares in the last quarter. Finally, Fosun International Ltd raised its position in shares of VBI Vaccines by 43.6% during the 2nd quarter. Fosun International Ltd now owns 1,051,126 shares of the biopharmaceutical company’s stock worth $1,156,000 after acquiring an additional 319,045 shares in the last quarter. 26.49% of the stock is currently owned by institutional investors and hedge funds.</p>
      <p>
        <b>VBI Vaccines Company Profile</b>
      </p>
      <p>VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company offers Sci-B-Vac, a prophylactic hepatitis B vaccine for adults, children, and newborns; and eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines that closely mimic the structure of the target virus.</p>
      <p>See Also: <a href="https://www.marketbeat.com/financial-terms/risk-of-owning-bonds/">Bond</a></p>
      <figure>
        <img src="https://www.marketbeat.com/images/flyonthewall.png"/>
      </figure>
    </article>
  </body>
</html>